Viking Therapeutics Quarterly Income Statement
NASDAQ: VKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viking Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Viking Therapeutics generated $0 in revenue, up 0.0% from the same quarter a year earlier. Viking Therapeutics reported a net loss of $128.0 million, compared with a loss of $65.6 million a year earlier. Diluted earnings per share came in at -$1.10.
Summary generated from market data by MetaCap's automated system. Methodology
Viking Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 132.60M | 164.13M | 164.74M | 98.56M | 74.57M | 55.47M | 46.24M | 36.56M | 34.05M | 34.07M | 29.29M | 27.27M |
| Research & Development | 115.75M | 150.15M | 153.46M | 89.95M | 60.15M | 41.39M | 30.99M | 22.79M | 23.77M | 24.10M | 20.50M | 18.38M |
| Operating Income | -132.60M | -164.13M | -164.74M | -98.56M | -74.57M | -55.47M | -46.24M | -36.56M | -34.05M | -34.07M | -29.29M | -27.27M |
| Other Income (Expense) | 4.58M | 5.80M | 7.08M | 7.77M | 9.01M | 9.84M | 10.82M | 11.62M | 11.80M | 6.72M | 4.68M | 4.73M |
| Net Income | -128.02M | -158.32M | -157.66M | -90.79M | -65.56M | -45.63M | -35.42M | -24.94M | -22.25M | -27.36M | -24.61M | -22.53M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.10 | -1.37 | -1.39 | -0.81 | -0.58 | -0.41 | -0.33 | -0.22 | -0.20 | -0.26 | -0.24 | -0.23 |
| EPS (Diluted) | -1.10 | -1.37 | -1.39 | -0.81 | -0.58 | -0.41 | -0.33 | -0.22 | -0.20 | -0.26 | -0.24 | -0.23 |
| Shares Outstanding (Basic) | 116.26M | 115.57M | — | 112.32M | 112.13M | 112.07M | — | 110.91M | 110.39M | 103.46M | — | 99.85M |
| Shares Outstanding (Diluted) | 116.26M | 115.57M | — | 112.32M | 112.13M | 112.07M | — | 110.91M | 110.39M | 103.46M | — | 99.85M |
This table shows 12 quarterly periods of Viking Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 11 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow VKTX's reporting calendar. What is a income statement?